Loading...
Market
What will be Miplyffa's market share in the Niemann-Pick disease type C treatment market by Dec 31, 2024?
2
Resolution / Starting Odds
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Market analysis reports from healthcare industry analysts
Story
FDA Approves Zevra's Miplyffa, First Treatment for Niemann-Pick Disease Type C, Valued at $150 Million
Sep 20, 2024, 03:42 PM
The U.S. Food and Drug Administration (FDA) has approved Zevra Therapeutics' drug, Miplyffa (arimoclomol), for the treatment of Niemann-Pick disease type C (NPC). This approval marks the first treatment for this rare and fatal genetic disorder. The approval also makes Zevra eligible to receive a Priority Review Voucher, valued at approximately $150 million. Miplyffa is approved for use in combination with miglustat for patients aged 2 and older. The New Drug Application (NDA) for arimoclomol had a PDUFA date of September 21, 2024. The US FDA noted that this is the first treatment to get a nod for the condition.
View original story
Similar markets
Less than 20% • 25%
20% - 40% • 25%
40% - 60% • 25%
More than 60% • 25%
Less than 25% • 25%
25%-50% • 25%
51%-75% • 25%
More than 75% • 25%
Less than 100 • 25%
100 - 500 • 25%
500 - 1000 • 25%
More than 1000 • 25%
Less than 500 • 25%
500-1000 • 25%
1001-2000 • 25%
More than 2000 • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,001 to 10,000 • 25%
More than 10,000 • 25%
Less than $50 million • 25%
$50 million - $100 million • 25%
$100 million - $150 million • 25%
More than $150 million • 25%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,000 to 10,000 • 25%
More than 10,000 • 25%
<10% • 25%
10-25% • 25%
25-50% • 25%
>50% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%